FierceBiotech |
ViaCyte bags $10M for diabetes cell therapies
FierceBiotech This treatment is intended for high-risk Type 1 diabetes patients—those who experience severe hypoglycemic episodes, who have “brittle diabetes,” where blood glucose levels swing up and down, or who are less able or unable to spot symptoms of low ... ViaCyte Raises $10M, Moves to Human Trial with New Diabetes Product |
Social Plugin